Resources

Resources are available for you to read, which may be useful in specific situations (such as when trying to make Epidyolex available for prescription in your clinic/hospital, or in discussions with patients).

Product links

Epidyolex Summary of Product Characteristics (SmPC)
Read more
Patient Information Leaflet
Read more

Articles and leading opinions

how to take
Video
How to take Epidyolex
More
Hide
This short video talks through 10 steps on how to take Epidyolex and what’s in the box
GW Pharmaceuticals
Watch video
titration thumbnail
Key Opinions
Titration and therapeutic dose
More
Hide
An interview with Professor Ulrich Brandl
Director of the Department of Paediatric Neurology University Hospital Jena, Germany
Watch video
managing
Key Opinions
Managing Interactions
More
Hide
An interview with Professor Ulrich Brandl
Director of the Department of Paediatric Neurology University Hospital Jena, Germany
Watch video
dialog_conference_article
Conference
Epilepsy DiaLoGS: Leading Conversation
More
Hide
Join your peers, expand your knowledge and share expertise on cannabinoid science and medicines
GW Pharmaceuticals
Read more
Committed to making a difference
Key Opinions
GW Pharmaceuticals: Committed to making a difference
More
Hide
A message from Chris Tovey
Watch video
epilepsy focus
Conference
Epilepsy FOCUS: hear from experts
More
Hide
Socially distant but intellectually engaged. Register to Epilepsy FOCUS and gain access to e-learning videos...
GW Pharmaceuticals
Read more
Understanding-the-Epidyolex-Label
Key Opinions
Understanding the Epidyolex Label
More
Hide
An interview with Professor Richard Chin
Watch video
clinical-experience
Key Opinions
Clinical Experience with Epidyolex
More
Hide
An interview with Professor Richard Chin
Watch video
Taking_Dravet_Syndrome_Head
Article
Taking Dravet Syndrome Head On, Together
More
Hide
The journey I have been on with my son Arlo has been far from easy…
Galia Wilson, Chair and Trustee, Dravet Syndrome UK
Read more
Sign up and stay up to date

Receive promotional communications and notifications about open-label extension data, our latest conference activity, key opinions from leading researchers and prescribers in cannabinoid therapy.